Breaking News Instant updates and real-time market news.

EOLS

Evolus

$14.26

0.57 (4.16%)

, AGN

Allergan

$164.07

34.42 (26.55%)

13:26
06/25/19
06/25
13:26
06/25/19
13:26

Evolus can benefit from 'distraction' at Allergan, says Stifel

After AbbVie (ABBV) announced its intention to acquire Allergan (AGN), Stifel analyst Annabel Samimy said the former clearly sees the latter's Medical Aesthetics business "as a premier, durable, cash-pay franchise and a leader in its field." However, she noted that AbbVie committed to keeping it as a separate business under the Allergan name, which leads Samimy to believe that a spinoff of aesthetics remains a possibility. She also said she would expect "meaningful distraction" at Allergan, "as typical in the midst of an acquisition," which can benefit competitor Evolus (EOLS) as it launches Jeuveau. Samimy, who concluded that she sees today's news potentially bringing interest back to the "washed out" biopharma group, names Revance (RVNC), Aerie Pharmaceuticals (AERI), TherapeuticsMD (TXMD) and Kala Pharmaceuticals (KALA) as being among the potentially attractive targets.

EOLS

Evolus

$14.26

0.57 (4.16%)

AGN

Allergan

$164.07

34.42 (26.55%)

ABBV

AbbVie

$66.52

-11.89 (-15.16%)

RVNC

Revance

$12.15

0.59 (5.10%)

AERI

Aerie Pharmaceuticals

$30.34

0.13 (0.43%)

TXMD

TherapeuticsMD

$2.58

0.06 (2.38%)

KALA

Kala Pharmaceuticals

$5.78

0.2 (3.58%)

  • 25

    Jun

  • 25

    Jun

  • 10

    Jul

  • 10

    Jul

  • 11

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

  • 15

    Aug

  • 16

    Sep

EOLS Evolus
$14.26

0.57 (4.16%)

06/11/19
LEHM
06/11/19
INITIATION
Target $13
LEHM
Underweight
Evolus initiated with an Underweight at Barclays
Barclays analyst Balaji Prasad started Evolus with an Underweight rating and $13 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
06/10/19
WELS
06/10/19
NO CHANGE
WELS
Evolus drug delay a positive for Allergan, says Wells Fargo
Wells Fargo analyst David Maris wrote a flash comment that Evolus' (EOLS) receiving a notice from the EC requesting supplementary information from the EMA/CHMP as part of their review of Nuceiva, a potential competitor to Botox, is a positive for Allergan (AGN), as it delays the marketing authorization application, or MAA, decision for Nuceiva in Europe. Maris kept an Outperform rating on Allergan.
05/21/19
EAMC
05/21/19
INITIATION
Target $6
EAMC
Sell
Evolus initiated with a Sell at Empire
Empire started coverage of Evolus with a Sell rating and $6 price target.
06/25/19
MZHO
06/25/19
NO CHANGE
Target $171
MZHO
Buy
Allergan price target lowered to $171 from $194 at Mizuho
Mizuho analyst Irina Koffler lowered her Botox Cosmetic and CoolSculpt estimates after conducting a survey of 20 dermatologists and plastic surgeons, who gave the impression that that the Botox franchise will be pressured by Evolus (EOLS) and other new entrants. Koffler cut her price target on Allergan shares to $171 from $194 based on the lowered estimates, but maintains a Buy rating on the stock, stating that it is "widely expected" that the company will make a strategic announcement that begins the preliminary work of separating the company in the next 1-2 months.
AGN Allergan
$164.07

34.42 (26.55%)

06/25/19
PIPR
06/25/19
NO CHANGE
PIPR
Neutral
Piper says 'willing to listen' to AbbVie reasoning for Allergan acquisition
Ahead of the call to discuss AbbVie's (ABBV) planned $63B acquisition of Allergan (AGN), Piper Jaffray analyst Christopher Raymond said his first reaction to the deal could be summed up with the phrase "two turkeys don't make an eagle," but he is "willing to listen" despite his skepticism about the transaction. Though he cannot say he is "excited at the prospect of AbbVie entering the field of medical aesthetics," EPS accretion of 10% in year one and over 20% at peak, and the potential for meaningful deleveraging and cost cutting, has his attention, Raymond said. He keeps a Neutral rating on AbbVie based on his initial reaction to the deal announcement.
06/25/19
WELS
06/25/19
NO CHANGE
WELS
Outperform
Deals with premiums like Allergan's 'rarely killed,' says Wells Fargo
After Abbvie (ABBV) announced an agreement to acquire Allergan (AGN) for $120 per share of cash and a remaining $68 in AbbVie shares, Wells Fargo analyst David Maris said he views the deal as a good alternative for Allergan versus the current share price, but he is not convinced its a better long term alternative given the eventual biosimilar threat to Abbvie's blockbuster drug Humira. With that said, Maris tells investors that "deals at such premiums are rarely killed because of a bad strategic fit or longer -term value outlook in the absence of other bidders." Though he would not completely rule out an activist investor disrupting the deal, he thinks it is unlikely given there has been a strategic review of the company for some time. Maris, who said he thinks the deal could go through, keeps an Outperform rating on Allergan shares.
06/25/19
LEER
06/25/19
NO CHANGE
LEER
Outperform
Bid of $188 for Allergan 'too low,' others may pursue as well, says SVB Leerink
SVB Leerink analyst Marc Goodman is not surprise that one of the large pharma companies has made a bid on Allergan (AGN) given the multi-year stock weakness. However, he believes a $188 price is "too low," as he "can't believe that Allergan is not being taken out at least at $200," which "begs the question" whether this was a process or is AbbVie (ABBV) "opportunistically pursuing a wounded stock." If it is the latter, Goodman believes this bid could initiate others to pursue Allergan as well. He has an Outperform rating on Allegan's shares.
06/25/19
LEHM
06/25/19
UPGRADE
LEHM
Equal Weight
Allergan upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Balaji Prasad upgraded Allergan (AGN) to Equal Weight from Underweight to reflect the company's agreement to be acquired by AbbVie (ABBV).
ABBV AbbVie
$66.52

-11.89 (-15.16%)

RVNC Revance
$12.15

0.59 (5.10%)

02/15/19
WELS
02/15/19
INITIATION
Target $17
WELS
Market Perform
Revance initiated with a Market Perform at Wells Fargo
Wells Fargo analyst David Maris initiated Revance (RVNC) with a Market Perform rating and $17 price target. In a research note to investors, Maris says he believes the market is already anticipating a success of Revance's lead program RT002, and as such, see risk to the downside. Additionally, Maris notes that an approval in glabellar lines would only make Revance "partially competitive" to Allergan's (AGN) Botox.
06/11/19
LEHM
06/11/19
INITIATION
Target $28
LEHM
Overweight
Revance initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Revance Therapeutics with an Overweight rating and $28 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
03/01/19
RHCO
03/01/19
NO CHANGE
Target $29
RHCO
Buy
Revance price target lowered to $29 from $58 at SunTrust
SunTrust analyst Ashwani Verma lowered his price target on Revance to $29 after its wider than expected Q4 loss, saying the lower cost alternatives to Botox "changes the market reality" for the company. The analyst believes that there are few catalysts for Revance this year, but sees 2020 as rich with potentially positive news flow with expected regulatory approval for its glabellar lines product and the results of the phase 2 study of its Plantar Fasciitis / Upper Limb Spasticity program. Verma is keeping his Buy rating on Revance.
03/11/19
GUGG
03/11/19
NO CHANGE
Target $190
GUGG
Buy
Allergan has 'trapped value,' but unlocking will take time, says Guggenheim
Guggenheim analyst Seamus Fernandez reiterated his Buy rating on Allergan (AGN) shares after Rapastinel's Phase 3 failure, stating that he believes the stock's current price already assumes major challenges and he thinks a major restructuring or sale of the business would be viable options to unlock that value. While Allergan's Botox and aesthetics business is not without risks, such as Revance's (RVNC) long-acting neurotoxin and Evolus' (ELOS) Jeuveau, his analysis suggests Botox and aesthetics are worth $46B-$49B, Fernandez tells investors. As a result of lower pipeline estimates and his base case sum of the parts-based valuation of $170 per share, Fernandez lowered his price target on Allergan shares to $190 from $219.
AERI Aerie Pharmaceuticals
$30.34

0.13 (0.43%)

06/11/19
ADAM
06/11/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals Q2 script numbers too high, says Canaccord
Canaccord analyst Dewey Steadman said Aerie Pharmaceuticals' Rhopressa and Rocklatan prescriptions were likely impacted by the Memorial Day holiday. As a result, the analyst does not believe the prescription run rate can meet his/consensus revenue expectations for the quarter and that estimates will likely need to come down ahead of its Q2 results. Steadman maintained his Buy rating and $56 price target on Aerie Pharmaceuticals shares.
05/10/19
ADAM
05/10/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals price target cut to $56 from $65 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target for Aerie Pharmaceuticals to $56 from $65 following the company's Q1 results, saying Aerie posted a sequential revenue decline from Q4 and a top- line miss relative to consensus expectations as growth from Rhopressa meaningfully slowed from its post-launch ramp last year. In a research note to investors, Steadman says he thinks Aerie will be highly dependent on a return to Rhopressa growth coupled with exceptionally strong Rocklatan launch metrics to meet its $110M-$120M 2019 revenue guide after posting only ~$11M in Q1 revenue. Steadman "reluctantly" maintains a Buy rating, saying the need to flawlessly execute, coupled with a lack of binary pipeline catalysts, leave him to believe that Aerie shares will likely be rangebound for the near future.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
06/11/19
CANT
06/11/19
NO CHANGE
Target $85
CANT
Overweight
Aerie drugs transforming glaucoma treatment space, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros says that with a year's worth of scripts reported for Rhopressa and an early first month look at the Rocklatan launch, he remains confident that Aerie Pharmaceuticals' two drugs are transforming the glaucoma treatment space. With "superior efficacy established" over the number-one prescribed prostaglandin, Aerie's portfolio of glaucoma treatments is best in class, Piros tells investors in a research note. He reiterates an Overweight rating on the shares with an $85 price target.
TXMD TherapeuticsMD
$2.58

0.06 (2.38%)

06/12/19
CANT
06/12/19
NO CHANGE
Target $13
CANT
Overweight
TherapeuticsMD price target lowered to $13 from $27 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for TherapeuticsMD to $13 from $27, driven by multiple contraction, given increasing headwinds from macro factors. The analyst reiterates an Overweight rating on the shares.
06/11/19
OPCO
06/11/19
NO CHANGE
OPCO
TherapeuticsMD price target lowered to $10 from $13 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target on TherapeuticsMD to $10 from $13, and his FY19 sales estimates to $25.9M from $32.9M, after the company provided revenue guidance below consensus. Olson, however, kept an Outperform rating on the company based on the potential for TherapeuticsMD to "successfully penetrate and expand the market for treatment of menopausal symptoms" with its two products, Imvexxy and Bijuva.
06/11/19
COWN
06/11/19
NO CHANGE
Target $9
COWN
Outperform
TherapeuticsMD price target lowered to $9 from $16 at Cowen
Cowen analyst Ken Cacciatore lowered his price target on TherapeuticsMD to $9 from $16 following its analyst day meeting. The company provided initial 2019 revenue projections for Imvexxy, Bijuva, and Annovera, which were modestly below expectations. Despite the shortfall, he still believes the products are sufficiently differentiated and the company is well capitalized so that it can reach profitability in the second half of 2021. Cacciatore maintained his Outperform rating on TherapeuticsMD shares.
06/11/19
JPMS
06/11/19
NO CHANGE
Target $6
JPMS
Overweight
TherapeuticsMD price target lowered to $6 from $8 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for TherapeuticsMD to $6 from $8 while keeping an Overweight rating on the shares. The analyst reduced his estimates after the company's 2019 guidance coming in below his expectations, reflecting "more challenging" gross-to-net dynamics for Imvexxy as well as a softer outlook for its vitamin business. However, Schott continues to see Imvexxy, Bijuva and Annovera as well positioned in their respective markets, which he believes should support "very strong uptake" over the next several years.
KALA Kala Pharmaceuticals
$5.78

0.2 (3.58%)

03/14/19
JEFF
03/14/19
INITIATION
Target $15
JEFF
Buy
Jefferies starts Kala Pharmaceuticals with Buy rating, $15 price target
Jefferies analyst Biren Amin initiated coverage of Kala Pharmaceuticals with a Buy rating and $15 price target. The company has reformulated loteprednol, an ocular steroid, with mucus-penetrating particles to provide superior penetration versus traditional steroid eye drops, Amin tells investors in a research note. It lead asset Inveltys is launching for use in post-operation surgeries and investors assume a slow launch for a product that could generate $150M in peak sales, the analyst adds. Further, he believes KPI-121 0.25% provides a "second and more meaningful catalyst" with Stride 3 pivotal data in dry eye at year-end 2019.
03/14/19
03/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/19
OPCO
04/24/19
INITIATION
Target $11
OPCO
Outperform
Kala Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated Kala Pharmaceuticals with an Outperform and $11 price target.
04/25/19
04/25/19
INITIATION
Target $11

Outperform
Oppenheimer initiates Kala with Outperform, sees attractive growth story
As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Kala Pharmaceuticals with an Outperform rating and $11 price target. With strong initial uptake of Inveltys, and KPI-121 regulatory catalyst in Q3, the analyst believes Kala Pharmaceuticals is well positioned for top line growth. His channel checks with ocular surgeons support Inveltys prescription growth over the next twelve months. Separately, he believes KPI-121 may address a significant unmet need in the nascent dry eye disease market.

TODAY'S FREE FLY STORIES

CNS

Cohen & Steers

$51.92

-0.415 (-0.79%)

16:23
07/17/19
07/17
16:23
07/17/19
16:23
Earnings
Cohen & Steers reports Q2 EPS 62c, consensus 63c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:22
07/17/19
07/17
16:22
07/17/19
16:22
Hot Stocks
eBay reaches commercial agreement with Paytm Mall »

eBay has taken two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:21
07/17/19
07/17
16:21
07/17/19
16:21
Hot Stocks
eBay achieves over $270M of GMV during Q2 »

eBay accelerated adoption…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:20
07/17/19
07/17
16:20
07/17/19
16:20
Hot Stocks
eBay grew active buyers by 4% across its platforms in Q2 »

In the second quarter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/17/19
07/17
16:20
07/17/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 17th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYY

Sysco

$71.75

-0.865 (-1.19%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Initiation
Sysco initiated  »

Sysco initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

  • 25

    Sep

CCI

Crown Castle

$131.60

-1.08 (-0.81%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
Crown Castle reports Q2 EPS 52c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TSC

TriState Capital

$19.71

-0.31 (-1.55%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
TriState Capital reports Q2 EPS 47c, consensus 45c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 23

    Sep

PLXS

Plexus

$59.86

-1.6 (-2.60%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
Plexus sees Q4 EPS 81c-91c, consensus 96c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
eBay raises FY19 adjusted EPS view to $2.70-$2.75 from $2.64-$2.70 »

Consensus $2.69. Lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

UMPQ

Umpqua Holdings

$16.48

-0.24 (-1.44%)

16:18
07/17/19
07/17
16:18
07/17/19
16:18
Earnings
Umpqua Holdings reports Q2 EPS 51c, consensus 38c »

Q2 provision for loan and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PLXS

Plexus

$59.86

-1.6 (-2.60%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Earnings
Plexus reports Q3 EPS 81c, consensus 81c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

URI

United Rentals

$131.55

-6.05 (-4.40%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Earnings
United Rentals narrows FY19 revenue view to $9.15B-$9.45B from $9.15B-$9.55B »

Consensus $9.36B. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Earnings
eBay raises FY19 adjusted EPS view to $2.70-$2.75 from $2.64-$2.70 

FY19 consensus $2.69.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

FNLC

The First Bancorp

$25.51

-0.43 (-1.66%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Earnings
The First Bancorp reports Q2 EPS 59c vs. 53c last year »

Reports book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFG

FBL Financial

$63.86

-0.08 (-0.13%)

, VOYA

Voya Financial

$56.09

-0.785 (-1.38%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Hot Stocks
FBL Financial names Kelli Eddy COO »

FBL Financial Group (FFG)…

FFG

FBL Financial

$63.86

-0.08 (-0.13%)

VOYA

Voya Financial

$56.09

-0.785 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 07

    Aug

EGBN

Eagle Bancorp

$53.43

-1.07 (-1.96%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Earnings
Eagle Bancorp reports Q2 EPS $1.08, consensus $1.12 »

The net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 11

    Sep

  • 23

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/17/19
07/17
16:17
07/17/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$143.07

-0.47 (-0.33%)

16:16
07/17/19
07/17
16:16
07/17/19
16:16
Earnings
IBM reports Q2 gross margin up 100 basis points »

Reports Q2 Cloud &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

URI

United Rentals

$131.55

-6.05 (-4.40%)

16:16
07/17/19
07/17
16:16
07/17/19
16:16
Earnings
United Rentals reports Q2 EPS $4.74, consensus $4.46 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:16
07/17/19
07/17
16:16
07/17/19
16:16
Earnings
eBay sees Q3 adjusted EPS 62c-65c, consensus 63c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/17/19
07/17
16:16
07/17/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:15
07/17/19
07/17
16:15
07/17/19
16:15
Earnings
eBay reports Q2 adjusted EPS 68c, consensus 62c »

Reports Q2 revenue $2.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

SLG

SL Green Realty

$81.26

-0.62 (-0.76%)

16:14
07/17/19
07/17
16:14
07/17/19
16:14
Earnings
SL Green Realty reports Q2 FFO $1.82, consensus $1.73 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

IBM

IBM

$142.98

-0.56 (-0.39%)

16:14
07/17/19
07/17
16:14
07/17/19
16:14
Earnings
IBM backs FY19 adjusted EPS view of at least $13.90, consensus $13.90 »

Through the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.